Activation of hepatic stellate cells (HSC), the major effector in hepatic fibrogenesis, is coupled with sequential alterations in expression of genes, including the upregulation of platelet-derived growth factor-b receptor (PDGF-bR) and epidermal growth factor receptor (EGFR), as well as the down-regulation of the peroxisome proliferator-activated receptor-g (PPARg). However, the relationship among the alterations in expression of the genes and the activation of their signaling in activated HSC remains obscure. We recently showed that curcumin, the yellow pigment in curry, inhibited cell growth and induced gene expression of endogenous PPARg in activated HSC in vitro. The present study is to elucidate the underlying mechanisms, focusing on the impacts of PDGF and EGF signaling. It is hypothesized that the interruption of the PDGF and EGF signaling pathways by curcumin might stimulate gene expression of PPARg in activated HSC. Our results in this report indicate that the activation of PDGF or EGF signaling by exogenous PDGF or EGF inhibits PPARg gene expression in passaged HSC. Curcumin interrupts PDGF and EGF signaling demonstrated by inhibiting tyrosine phosphorylation of PDGF-bR and EGFR and by reducing the levels of phosphorylated phosphatidylinositol-3 kinase (PI-3K/ AKT), extracellular signal-regulated kinase (ERK) and the Jun N-terminal kinase (JNK). The blockade of PI-3K/AKT, ERK or JNK signaling negatively regulates PPARg gene expression in activated HSC, leading to the reduction in cell growth, including inducing cell arrest and apoptosis. Our results collectively demonstrate that the interruption of the PDGF and EGF signaling pathways by curcumin stimulates gene expression of PPARg in activated HSC. These results provide novel insights into the mechanisms of curcumin in the induction of PPARg gene expression in activated HSC.
Hepatic stellate cells (HSC) are the most relevant cell type for the development of liver fibrosis. 1, 2 During liver injury, HSC become activated and trans-differentiate into myofibroblastlike cells. The process is called HSC activation. Enhanced HSC proliferation is a dramatic feature during the pathogenesis of liver fibrosis. It is mainly triggered by autocrine/ paracrine activation of the signaling for mitogenic plateletderived growth factor-b (PDGF) and epidermal growth factor (EGF). [3] [4] [5] [6] The process of HSC activation is coupled with the up-expression of receptors for PDGF and EGF, 4, 7, 8 as well as the dramatic down-expression of peroxisome proliferatoractivated receptor-g (PPARg). [9] [10] [11] Both PDGF-bR and EGFR contain intrinsic tyrosine kinase activity. Upon binding to their ligands, the receptors become phosphorylated at tyrosine residues, leading to the activation of their downstream signaling, of which the mitogen-activated protein kinase (MAPK) pathways and the phosphatidylinositol 3-kinase (PI-3K) pathway are the major signaling routes. 12, 13 The MAPK family includes the extracellular signal-regulated kinase (ERK) pathway and the Jun N-terminal kinase (JNK) pathway. Activated PI-3K generates several phosphoinositols, leading to AKT activation by phosphorylation at Thr 308 and Ser 473 , 14 which is inhibited by activation of phosphatase and tensin homolog (PTEN). 13 It is well-known that these signaling pathways regulate multiple biological processes, including gene expression, cell proliferation and survival. normal liver, its expression and its activity are dramatically diminished during HSC activation in vitro and in vivo. [9] [10] [11] Activation of PPARg induces cell arrest and apoptosis of activated HSC. [9] [10] [11] Introduction of exogenous PPARg cDNA is sufficient to reverse the morphology of activated HSC to the quiescent phenotype. 15 Curcumin is the yellow pigment in curry from turmeric. It has received attention as a promising dietary supplement for cancer prevention [16] [17] [18] and the protection against fibrogenic insults. 19, 20 However, the underlying mechanisms remain incompletely understood. 21 We recently reported that curcumin induced gene expression of endogenous PPARg in activated HSC in vitro, which was a prerequisite in the curcumin inhibition of HSC growth, induction of apoptosis and suppression of extracellular matrix gene expression. [22] [23] [24] The aim of this study is to elucidate the mechanisms of curcumin in the induction of PPARg gene expression in activated HSC, focusing on the impact of PDGF and EGF signaling. It is hypothesized that the interruption of the PDGF and EGF signaling pathways by curcumin might stimulate gene expression of PPARg in activated HSC. Results in this report support our hypothesis and demonstrate that activation of PDGF or EGF signaling inhibits PPARg gene expression. Curcumin interrupts PDGF and EGF signaling, leading to the induction of gene expression of PPARg and the reduction of cell growth of activated HSC in vitro.
MATERIALS AND METHODS Materials
Curcumin (purity494%) was purchased from Sigma (St Louis, MO, USA) and used at 20 mM, unless indicated otherwise. PD68235, a specific PPARg antagonist, was kindly provided by Pfizer (Ann Arbor, MI, USA). 25 The PI-3K inhibitor LY294002 and the MEK inhibitor PD98059 were purchased from CalBiochem (La Jolla, CA, USA), and the JNK inhibitor SP600125 was purchased from Sigma. Recombinant PDGF and EGF were purchased from Cell Sciences (Canton, MA, USA).
Isolation and Culture of HSC HSC were isolated from Sprague-Dawley rats (200-250 g) as we described previously. 26 Cells were cultured in Dullbecco's modified Eagle's medium (DMEM) with 10% of fetal bovine serum (FBS). Semiconfluent HSC with 4-8 passages were used for experiments. In some of experiments, cells were serum-starved for 48 h in DMEM with 0.5% of FBS before treatment.
Western Blotting Analyses
Whole-cell extracts were prepared as we described. 26 Proteins were separated by SDS-PAGE with 10% of resolving gel, and transferred to PVDF membrane. Target proteins were respectively detected by primary antibodies against PPARg, phosphorylated types of PDGF-bR, EGFR, ERK1/2, JNK1/2 or AKT, and the corresponding non-phosphorylated types of total proteins; Bcl-2, Bax or cyclin D1, and subsequently by horseradish peroxidase-conjugated secondary antibodies (Santa Cruze Biotechnology, Santa Cruze, CA, USA). Protein bands were visualized by using a chemiluminescence reagent (Amersham Biosci, Piscataway, NJ, USA). In Western blotting analyses, the densities of bands were normalized with the internal invariable control b-actin. The level of target protein bands was densitometrically determined by using Quantity One s 4.4.1 (Bio-Rad). The variation in the density was expressed as fold changes compared to the control in the blot.
RNA Isolation and Real-Time PCR Total RNA was extracted by using TRI-Reagent s (Sigma), following the protocol provided by the manufacturer. Real-time PCR was carried out as described previously. 22 mRNA fold changes of target genes relative to the endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control were calculated as suggested by Schmittgen et al.
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The following primers were used in real-time PCR:
Plasmid Constructs
The PPARg promoter luciferase reporter plasmid pPPARgLuc contain the 5 0 -flanking region (À2776 bp) of the PPARg gene promoter in a luciferase reporter plasmid. 28 It was kindly provided by Dr Johan Auwerx (Pasteur Institute, Lille, France). 28 The plasmid pdn-PTEN or pwt-PTEN contains a full-length of cDNA encoding the dominant-negative form of PTEN or wild-type PTEN, respectively. They were kindly provided by Dr Christopher G Kevil (Louisiana State University Health Sciences Center in Shreveport). The plasmid pdn-ERK or pdn-JNK, contains a full length of cDNA encoding the dominant-negative form of ERK or JNK respectively, which were described previously. 29 The plasmid pa-ERK or pa-JNK contains cDNA encoding the constitutively active form of ERK or JNK, respectively, which were described previously. 29, 30 Transient Transfection Assays Semiconfluent HSC in six-well plastic plates were transiently transfected with a reporter plasmid (3 mg DNA/well, if no specific indication), by using LipofectAMINE s (Life Technologies), following the protocol provided by the manufacturer. Transfection efficiency was controlled by co-transfection of the b-galactosidase reporter plasmid pSVb-gal (1 mg/well) (Promega). Luciferase activity was measured using an automated luminometer (Turners). b-Galactosidase assays were performed using an assay kit from Promega Corp. Each treatment had a triplicate in every experiment. Each experiment was repeated at least three times. Luciferase activity was expressed as relative unit after normalization with b-galactosidase activity.
Analyses of Cell Growth
The number of viable cells was used to determine cell growth by using CellTiter 96
s AQueous Non-Radioactive Cell Proliferation Assay kit (Promega) (ie MTS assays).
Detection of Apoptotic HSC by TUNEL Pre-confluent HSC in slideflasks were serum starved for 24 h. Cells were subsequently treated as described for an additional 24 h. Cells were washed three times with cold PBS before fixation. Apoptotic HSC were detected by DeadEndt Fluorometric TUNEL System (Promega), following the protocol provided by the manufacturer.
Flow Cytometric Analyses of Apoptotic HSC Semiconfluent HSC were treated as indicated. Cells were harvested by brief trypsin/EDTA treatment and washed several times with cold PBS. HSC (Z1 Â 10 6 cells/each sample) were suspended in 2 ml of FACS buffer (1% FA buffer (Difco), 0.1% sodium azide and 1% FBS). Cells were fixed with ethanol, and then labeled with propidium iodide (PI; Sigma). Cells that were positively labeled with PI were detected by a Coulter s EPICS s XL-MCL flow cytometer. The rate of apoptosis was analyzed using its System IIt software, as described previously. 31 
Statistical Analysis
Differences between means were evaluated using an unpaired two-sided Student's t-test (Po0.05 was considered significant). Where appropriate, comparisons of multiple treatment conditions with control were analyzed by ANOVA with the Dunnett's test for post hoc analysis.
RESULTS

Exogenous PDGF or EGF Reduces Gene Expression of PPARc, which was Partially Eliminated by Curcumin
The process of HSC activation is coupled with the sequential upregulation of PDGF-bR and EGFR and activation of their signaling, as well as the dramatic reduction in expression of PPARg. 4, [7] [8] [9] [10] [11] Prior other studies have suggested the opposite functions of PDGF and PPARg in adipogenesis. 32, 33 To evaluate the effect of activation of PDGF and EGF signaling on regulation of gene expression of PPARg, exogenous PDGF and EGF were added to passaged HSC for an additional 24 h after the treatment with or without curcumin in serum-free media for 24 h. PPARg expression was determined by realtime PCR and Western blotting analyses. Passaged HSC cultured in serum-depleted media respond better to the stimulation of PDGF or EGF. 4, 31 As shown in Figure 1 , exogenous PDGF or EGF evidently inhibited PPARg expression at both levels of mRNA and protein in a dose-dependent manner. Compared with the control with no treatment (the first black column on the left), EGF at 80 ng/ml or PDGF at 30 ng/ml reduced the steady-state level of PPARg mRNA by 66 and 75%, respectively (Figure 1a and c) . The inhibitory effects of EGF and PDGF on the abundance of PPARg were verified by Western blotting analyses (Figure 1b and d) . However, if cells were preexposed to curcumin (20 mM), the inhibitory effect of EGF or PDGF was significantly reduced (Figure 1 ). For instance, compared with cells exposed to EGF at 80 ng/ml or PDGF at 30 ng/ml, the pre-exposure of cells to curcumin partially but significantly eliminated the reduction caused by EGF or PDGF, and increased the level of PPARg mRNA by 2.4-and 2.25-fold, respectively (Figure 1a and c) . 
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PPARg expression, which could be partially eliminated by curcumin.
Curcumin Reduces Tyrosine Phosphorylation of PDGF-bR and EGFR
Additional experiments were performed to elucidate the effect of curcumin on tyrosine phosphorylation of PDGF-bR and EGFR in activated HSC, which might lead to interruption of the signaling pathways of PDGF and EGF and inactivation of downstream MAPK and PI-3K/AKT. Pilot studies indicated that the peak of tyrosine phosphorylation of PDGF-bR or EGFR was within 15-20 min after the addition of FBS, which contains significant amounts of PDGF and EGF 4, 31 and that the process lasted no less than 60 min (data not shown). Cells were serum-starved in DMEM for 48 h, which made cells more sensitive to serum stimulation. [22] [23] [24] Serum-starved cells were pretreated with curcumin for 30 min before the stimulation with FBS (10%) for an additional 20 min. Whole-cell extracts were prepared. Phosphorylated PDGF-bR and EGFR were detected by Western blotting analyses using antibodies against phospho-PDGF-bR (1:2000) and EGFR (1:500), respectively. As shown in Total AKT was used as an internal control.
Activating PDGF and EGF signaling inhibits PPARc expression Y Zhou et al pwt-PTEN, or a plasmid of pdn-ERK, pdn-JNK or pdn-PTEN. The plasmid pPPARg-Luc is a PPARg promoter luciferase reporter plasmid, which contains the 5 0 -flanking region (À2776 bp) of the PPARg gene promoter subcloned in a luciferase reporter plasmid. 34 The cDNA expression plasmid pa-ERK, or pa-JNK, contains a fragment of cDNA encoding the constitutively active form of ERK (a-ERK), or JNK (a-JNK), respectively. The plasmid pwt-PTEN contains a full size of wild-type PTEN cDNA, which inhibits activation of PI-3K/AKT signaling. 35 Similarly, the plasmid pdn-ERK, pdn-JNK or pdn-PTEN contains a fragment of cDNA encoding the dominant-negative form of ERK (dn-ERK), JNK (dn-JNK) or PTEN (dn-PTEN), respectively. A total of 3.2 or 4.5 mg of plasmid DNA per well was used for the co-transfection of HSC in six-well culture plates. It included 2 mg of pPPARg-Luc, 0.5 mg of pSV-b-gal, and 0.7 mg (Figure 4a and d), or 2 mg (Figure 4b and c) of a cDNA-expressing plasmid at indicated doses and the empty vector pcDNA. The latter was used to ensure an equal amount of total DNA in transfection assays. After transfection, cells were serum-starved in DMEM for 24 h before the stimulation with FBS (10%) in the presence or absence of curcumin (20 mM) for an additional 24 h. As shown in Figure 4 by luciferase assays, compared with no treatment (the first columns on the left), the activation of ERK, JNK or PI-3K/AKT, respectively, by pa-ERK, pa-JNK (Figure 4a ), or by pdn-PTEN (Figure 4c ), significantly reduced luciferase activity. These results suggested that the activation of ERK, JNK or PI-3K/AKT signaling might inhibit the gene promoter activity of PPARg in HSC. Curcumin, as expected, dramatically stimulated the promoter activity of PPARg demonstrated by the increase in luciferase activity (the third columns on the left in Figure 4a and c). It was of interest to observe that the activation of ERK, JNK, or PI-3K/AKT, by pa-ERK, pa-JNK (Figure 4a ), or by pdn-PTEN (Figure 4c ), dose-dependently eliminated the stimulatory effect of curcumin on luciferase activity. In great contrast, the blockade of these signaling pathways by pdn-ERK, pdn-JNK (Figure 4b ), or by pwt-PTEN (Figure 4d ) caused a dose-dependent increase in luciferase activity. Wildtype PTEN acts as an 'off ' switch for PI-3K signaling. 35 These results collectively suggested that the alterations in the activity of ERK, JNK or PI-3K/AKT might negatively regulate the promoter activity of PPARg gene, leading to changes in gene expression of PPARg in HSC.
The Inhibition of ERK, JNK or PI-3K/AKT Activity Stimulates Gene Expression of PPARc in Activated HSC Chemicals LY294002 (LY), PD98059 (PD) and SP600125 (SP) are commonly used for specifically inhibiting the activity of PI-3K/AKT, ERK and JNK, respectively. To further test the assumption that the alteration of the activity of PDGF and EGF signaling might negatively regulate expression of PPARg gene in HSC, these chemicals were respectively used to selectively inhibit ERK, JNK or PI-3K. Semiconfluent HSC were transfected with the PPARg promoter luciferase reporter plasmid pPPARg-Luc. After recovery overnight, cells were serum-starved for 24 h in DMEM with 0.5% of FBS. Figure 5a demonstrated that each of the three specific inhibitors, like curcumin, caused a dose-dependent increase in luciferase activity, suggesting that the inhibition of ERK, JNK or PI-3K might stimulate the activity of the promoter of PPARg gene in passaged HSC.
To confirm the observation, serum-starved HSC were pretreated with LY294002 (LY), PD98059 (PD), or SP600125 (SP), at various concentrations, or with curcumin (Cur) at 20 mM, for 30 min before the stimulation with FBS (10%) for an additional 24 h. Gene expression of PPARg was evaluated by real-time PCR (Figure 5b ) and Western blotting analyses ( Figure 5c ). As shown in Figure 5b and c, compared with the control with no treatment (the second columns, or wells on the left), curcumin, as expected, significantly increased gene expression of PPARg (the first columns, or wells on the left). It was further observed that the treatment of HSC with each of the inhibitors led to a dose-dependent increase in PPARg expression at the levels of mRNA (Figure 5b ) and protein ( Figure 5c ). Taken together, these results indicated that the inhibition of ERK, JNK or PI-3K/AKT activity stimulated gene expression of PPARg, which supported the assumption that alteration of the activity of PDGF and EGF signaling might negatively regulate the expression of PPARg gene in HSC.
The Blockade of the PI-3K/AKT, ERK, and/or JNK Signaling Pathways Results in the Reduction in HSC Growth, which is Partially Eliminated by Inhibition of PPARc Activation Substantial evidence has indicated that the activation of PI-3K/AKT, JNK and/or ERK stimulates HSC proliferation. 6, 36, 37 We have previously demonstrated that the activation of PPARg was required for curcumin to inhibit HSC proliferation. 23 Our earlier study showed that curcumin inhibited PI-3K/AKT, ERK, and JNK activity ( Figure 3 ) and that the interruption of the signaling pathways for PI-3K/AKT, ERK and JNK induced gene expression of PPARg (Figures 4 and  5) . Prior experiments suggested that 10% of FBS might contain enough agonists to activate PPARg in HSC. 11, [22] [23] [24] The induction of PPARg expression resulted in the stimulation of its activity in cultured HSC. [22] [23] [24] It is of interest to evaluate the role of PI-3K/AKT, ERK, and JNK activity in the curcumin induction of gene expression of PPARg. Serumstarved HSC were divided into two groups. One group was treated with curcumin (20 mM), LY294002 (LY), PD98059 (PD) or SP600125 (SP) at the indicated concentrations, or with a mixture of the three inhibitors at the indicated concentrations in DMEM with FBS (10%) for 24 h. The other group was pretreated with the specific PPARg inhibitor PD68235 (PD 0 ) at 20 mM for 30 min before the addition of curcumin (20 mM), or each of the above-specific inhibitors, or the mixture of the inhibitors, at the indicated concentrations in the media with FBS (10%) for an additional 24 h. Cell growth was determined by numbers of viable cells using MTS assays. Results were expressed as changes in viable cells, compared to the cells with no treatment. As shown in Table 1 , for the first group, which had no pretreatment to inhibit the On comparing to each of the individual inhibitor, the mixture of the three inhibitors had a more potent inhibitory effect on HSC growth. For the second group, which had the pretreatment, it is of interest to observe that the inhibition of PPARg activation by the pretreatment of cells with PD68235 (PD 0 ) partially, but significantly, eliminated the inhibitory effect of each of the inhibitors, as well as the mixture of the three inhibitors (Table 1) . Taken together, these results indicated that the blockade of the PI-3K/AKT, JNK and/or ERK signaling pathways resulted in the reduction in HSC growth, which was partially eliminated by inhibition of PPARg activation. These results collectively suggested that the inhibition of cell growth of HSC by curcumin might result from the blockade of the PI-3K/AKT, ERK and JNK signaling, leading to the induction of gene expression of PPARg.
The Interruption of the PI-3K/AKT, ERK and JNK Signaling Pathways Induces Apoptosis of Activated HSC, which is Partially Counteracted by Inhibition of PPARc Activation Our prior results indicated that PPARg activation was a prerequisite in the curcumin induction of apoptosis of HSC. 22, 23 Additional experiments were performed to evaluate the effect of the interruption of the PI-3K/AKT, ERK and JNK signaling pathways on the curcumin induction of apoptosis of HSC. Serum-starved HSC were similarly divided into two groups, and pretreated with or without the specific PPARg inhibitor PD68235 (PD 0 ) (20 mM) for 30 min before the addition of curcumin (20 mM), LY294002 (LY), PD98059 (PD) or SP600125 (SP) at the indicated concentrations in the media with FBS (10%) for an additional 24 h. A portion of the cells was used for determination of apoptosis by flow cytometric analyses. Whole-cell extracts from the rest of the cells were prepared for analyses of cyclin D1 (Cln D1), a critical protein in stimulating cell cycle at the stage of G 0 /G 1 , and the apoptosis relevant proteins Bax and Bcl-2. As shown in Figure 6 by Western blotting analyses, compared with the control with no treatment (the second well in each blot), like curcumin (the first well in each blot), each of the inhibitors caused a dose-dependent reduction in the abundance of cyclin D1. On comparing with the control (the left well in each pair of a kinase inhibitor at the same dose), the pretreatment with the specific PPARg inhibitor partially eliminated the inhibitory effect of the kinase inhibitor and increased the abundance of cyclin D1 (the right well in each pair). The levels of Bcl-2 and Bax determine the fate of cells, that is, survival or apoptosis. Also as shown in Figure 6 , compared with the control with no treatment (the second well in each blot), curcumin, as expected, increased the level of proapoptotic Bax and reduced the abundance of antiapoptotic Bcl-2 (the first well in each blot). Like curcumin, each of Activating PDGF and EGF signaling inhibits PPARc expression Y Zhou et al the inhibitors caused a dose-dependent reduction in the abundance of Bcl-2 and an increase in the level of Bax. Inhibition of PPARg activation by the pretreatment with PD68235 partially abrogated the ability of the inhibitors to alter the levels of the proteins relevant to apoptosis. The ability of the inhibitors to induce apoptosis was confirmed by TUNEL staining (Figure 7 ) and by flow cytometric analyses (Table 2) . Similarly, this ability was partially eliminated by inhibition of PPARg activation with PD68235 (PD 0 ). Taken together, these results demonstrated that the blockade of the PI-3K/AKT, ERK and JNK signaling pathways induced apoptosis of activated HSC, which was partially counteracted by inhibition of PPARg activation. DISCUSSION HSC activation is mainly triggered by the release of mitogenic PDGF, EGF and fibrogenic transforming growth factorb 1 (TGF-b1) from Kupffer cells and activated HSC. 38 The process of HSC activation is coupled with the sequential up-expression of receptors for growth factors, including PDGF-bR, type I & II receptors for TGF-b 39, 40 and EGFR. 8 In addition, HSC activation coincides with a dramatic reduction in the abundance PPARg. [9] [10] [11] We previously proposed an antagonistic relationship between the activation of the signaling pathways for these growth factors and the gene expression of PPARg in HSC, that is, activation of the signaling pathways reduces the activity of PPARg by suppressing Figure 7 The blockade of the PI-3K/AKT, ERK, and/or JNK signaling pathways results in the induction of apoptosis, which is partially eliminated by the inhibition of PPARg activation. Serum-starved HSC were treated with or without curcumin (20 mM), or LY294002 (LY) (10 mM), or PD98059 (PD) (10 mM), or SP600125 (SP) (10 mM) for 24 h in the presence or absence of the PPARg antagonist PD68235 (PD 0 ) at 20 mM. Apoptotic HSC were detected by DeadEndt Fluorometric TUNEL System (Promega) and viewed using a fluorescent microscope. Nuclei of apoptotic cells were detected and labeled with green fluorescence indicated by arrows. Nuclei of HSC were stained in blue with DAPI. Representative views (n ¼ 3) from each treatment were presented (original Â 40).
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PPARg gene expression during HSC activation, whereas activation of PPARg results in the interruption of the signaling pathways, leading to the inhibition of HSC activation. 24 Our recent results supported the proposal and demonstrated an antagonistic relationship between the activation of TGF-b signaling and the gene expression of PPARg in HSC. 24 The attention of the current study was paid to the role of PDGF and/or EGF signaling in the curcumin induction of PPARg gene expression in activated HSC. Results in this report demonstrated that exogenous PDGF or EGF caused a dosedependent reduction in PPARg gene expression in passaged HSC (Figure 1) . Curcumin interrupted the signaling pathways for PDGF and EGF in activated HSC by reducing the level of tyrosine phosphorylation of PDGF-bR and EGFR and inhibiting the activity of ERK, JNK and PI3/AKT (Figures 2  and 3 ). The activity of the PI-3K/AKT, ERK or JNK signaling pathway negatively regulated gene expression of PPARg in activated HSC in vitro (Figures 4 and 5) . The blockade of PI-3K/AKT, ERK or JNK signaling stimulated PPARg expression ( Figure 5 ). In addition, the interruption of the PI-3K/AKT, ERK and JNK signaling pathways resulted in the reduction in cell growth and the induction of apoptosis of activated HSC, which were partially eliminated by the inhibition of PPARg activation (Figures 6 and 7 and Tables 1  and 2 ). Taken together, our results suggested that the activity of PDGF or EGF signaling might negatively regulate gene expression of PPARg in activated HSC in vitro.
One of the dramatic features during HSC activation is enhanced cell growth, triggered by autocrine/paracrine activation of the signaling for PDGF and EGF. [3] [4] [5] [6] The MAPK pathways and the PI-3K/AKT pathway are their major downstream signaling cascades. [41] [42] [43] In this study, we hypothesized that the activation of PDGF and EGF signaling pathways might suppress gene expression of PPARg in HSC. Curcumin might interrupt PDGF and EGF signaling, leading to the relief of the inhibitory effect on PPARg gene expression in activated HSC. Our results in the present report demonstrated that activation of PDGF and/or EGF signaling suppressed gene expression of PPARg and reduced the abundance of PPARg in HSC (Figure 1 ). The activation of the downstream cascades of PDGF and EGF signaling, including PI-3K/AKT, JNK or ERK, reduced the gene promoter activity of PPARg (Figure 4) . In contrast, the inhibition of the downstream cascades induced gene expression of PPARg ( Figure 5 ). This observation is supported by prior other studies. It was found that PDGF inhibited PPARg transactivation activity in HSC transfected with a PPARg cDNA expression plasmid, 9 and that this inhibitory effect of PDGF was blocked by the inhibition of the MAPK signaling cascade. 9 We previously demonstrated that curcumin inhibited cell proliferation and induced apoptosis of activated HSC. [22] [23] [24] The underlying mechanisms remain largely to be defined. The signaling pathways of PI-3K/AKT, ERK and JNK are critically relevant to cell proliferation and cell survival in many cell types, including in HSC. [44] [45] [46] Curcumin reduced the level of tyrosine phosphorylation of PDGF-bR and EGFR and inhibited the activity of ERK, JNK and PI3/AKT Activating PDGF and EGF signaling inhibits PPARc expression Y Zhou et al (Figures 2 and 3) , leading to the interruption of the mitogenic PDGF and EGF signaling pathways. Our results further demonstrated that the inhibition of PI-3K/AKT, ERK or JNK activity by specific inhibitors dose-dependently reduced cell growth and induced apoptosis of passaged HSC (Figures 6 and 7 and Tables 1 and 2 ). Moreover, it was of interest to observe that the inhibitory effect was, partially but significantly, abrogated by the pretreatment of cell with PD68235, a special inhibitor of PPARg activity (Figures 6 and  7 and Tables 1 and 2 ). These results suggested that the induction of PPARg gene expression by curcumin and the stimulation of its activity might mediate the effect of the blockade of the PI-3K/AKT, ERK and JNK signaling pathways on the inhibition of cell growth of HSC. Additional experiments using siRNA to specifically block the curcumin induction of PPARg expression will directly demonstrate the involvement of PPARg gene expression in the inhibitory process.
Based on our prior and current observations, a model is proposed in Figure 8 to explain the mechanisms of curcumin in the induction of PPARg gene expression and the inhibition of cell growth, focusing on the involvement of PDGF and EGF signaling in the process. Curcumin interrupts the signaling pathways for PDGF and EGF by reducing the level of Activating PDGF and EGF signaling inhibits PPARc expression Y Zhou et al
